ER、PR、Her-2在乳腺癌中的表达

目的 探讨乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(Her-2)的表达与临床特征的关系.方法 用免疫组织化学法检测311例乳腺癌组织中ER、PR、Her-2的表达.结果 311例乳腺癌组织中Her-2阳性表达明显低于ER和PR,分别为87例(27.97%)、185例(59.49%)和195例(62.70%).与非浸润性乳腺癌相比,ER、PR在浸润性乳腺癌中的表达明显减少(P<0.05).ER的表达随乳腺癌TNM分期增加而减少(P<0.05),而PR和Her-2的表达与TNM分期无关(P0.05).与无腋窝淋巴结转移者相比,有腋窝淋巴结转移的乳腺癌组织中ER表达明显减少,Her-2表达明显增加(P<0.05).结论 ER、PR、Her-2与乳腺癌的临床特征密切相关,其可能参与乳腺痛的生物学行为调控,常规检测ER、PR、Her-2的表达可为乳腺癌治疗提供依据.

Expressions of ER, PR and Her-2 in breast cancer

Objective To investigate the relationship between expressions of estrogen receptor (ER), progesterone receptor(PR) and human epidermal growth factor receptor 2 (Her-2) in 311 cases of breast cancer tissue and their clinical feature. Methods The expressions of ER, PR and Her-2 were detected by immunohistochemistry in 311 cases of breast cancer tissue proved pathologically. Results The positive rate of ER, PR and Her-2 were 59.49 %, 62.70 % and 27.97 % respectively in breast cancer tissues. Compared with non-invasive breast cancer, the expressions of ER and PR significant decreased in invasive breast cancer (P<0.05). The expression of ER decreased to follow the elevation of TNM status of breast cancer (P<0.05). Compared with patients who had not metastasis in axiUary lymph node, the expressions of ER significantly decreased and the expressions of Her-2 significantly increased in patients who had metastasis in axillary lymph node (P<0.05). Conclusion These findings indicate that ER, PR and Her-2 are intimate correlation with clinical feature and maybe participate in biological behaviour regulation of breast cancer. The routine detecting of ER, PR and Her-2 may provide the evidence for breast cancer treatment.